Our patient’s original tumor at diagnosis was positive for AURKA by immuno-histochemistry (Figure 2C), and based on evidence in the literature (both preclinical/clinical)5,7,8,10 of efficacy of Alisertib (MLN8237) in the treatment of relapsed ATRT, she was treated with a trial of Alisertib monotherapy (60 mg/m2 by mouth once daily for 7 days of a 21-day treatment cycle). The gene discussed is AURKA; the disease is neoplasm.